[克罗恩病的概述和治疗更新]
Roy Frei1, Benjamin Misselwitz1
1Universitätsklinik für Viszerale Chirurgie und Medizin Klinik, Inselspital Bern und Universität Bern, Bern.
Therapeutische Umschau. Revue therapeutique
|December 14, 2023
概括
克罗恩病 (CD) 管理已经扩展到新的生物疗法,如选择性IL-23抑制剂和JAK抑制剂. 尽管取得了进展,但CD仍然无法治愈,这凸显了持续治疗开发的必要性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 是一种慢性炎症性肠病,具有复杂的病理生理学,涉及遗传易感性,肠道微生物群和免疫系统失调.
- 目前的治疗包括类固醇,但可以使用先进的疗法,如TNF抑制剂,IL-12 / 23抑制剂,整合素抑制剂,选择性IL-23抑制剂和JAK抑制剂.
- 手术切除是局部性CD的一个选择,而周围和抽性CD需要跨学科的管理.
研究的目的:
- 审查克罗恩病目前治疗选择的现状.
- 突出CD治疗的最新进展,包括新的生物和小分子疗法.
- 为了强调由于CD的不可治愈性,不断需要新的治疗策略.
主要方法:
- 对克罗恩病最近批准和新兴治疗方法的审查.
- 分析治疗选择,包括生物药物 (TNF抑制剂,IL抑制剂,整合素抑制剂) 和小分子 (JAK抑制剂).
- 考虑针对特定CD表现的手术干预.
主要成果:
- 现在有几种先进的治疗方法可用于CD,包括选择性IL-23抑制剂 (risankizumab) 和JAK抑制剂 (upadacitinib).
- 已建立的治疗方法,如TNF抑制剂,IL-12/23抑制剂和韦多利祖马布仍然是重要的选择.
- 手术为局部性CD提供了良好的结果,但需要仔细选择患者和控制疾病.
结论:
- 克罗恩病的治疗武器已经显著增加,为患者提供了更多的选择.
- 尽管治疗方面取得了进展,但克罗恩病仍然是一个具有挑战性的疾病,反应率不完整,这强调了需要继续进行研究和开发的必要性.
- 优化治疗需要全面了解CD病理生理学和跨学科合作.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Inflammatory Bowel Disease II: Crohn's Disease
253
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
253
Inflammatory Bowel Disease IV: Pharmacological Management
129
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
129
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335


